- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02980458
Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration
December 6, 2016 updated by: SocraTec R&D GmbH
Characterisation of Relative Bioavailability of a Generic Deferiprone Formulation in Comparison With a Marketed Reference Product in a Single Dose, 2-period-crossover Design Under Fasting Conditions; Controlled, Open, Randomised, no Blinded Study With Bioequivalence Assessment
The present study will be conducted in order to compare the bioavailability of the generic Test product (Deferiprone 500 Lipomed tablets, Lipomed AG, Switzerland) with a marketed Reference product (Ferriprox® film-coated tablets, Apotex Europe B.V., Germany) both containing 500 mg deferiprone.
For this issue the pharmacokinetics will be characterised after single dose administration of each one tablet.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will be performed in an open-label, randomised (order of treatments), single dose, 2 period cross-over design with a wash out phase of at least three treatment free days between both administrations.
Sample collection will be performed over eight hours after fasted administration.
This time is considered adequate for the determination of plasma concentration vs. time profiles long enough for reliable estimation of the extent of absorption, i.e. the AUC derived from measurements is expected to cover at least 80% of the AUC extrapolated to infinity for deferiprone
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Thüringen
-
Erfurt, Thüringen, Germany, 99084
- SocraTec R&D GmbH Clinical Pharmacology Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- sex: male
- ethnic origin: Caucasian
- age: 18 years or older
- body-mass index (BMI): >=18.5 kg/m² and <= 30.0 kg/m²
- good state of health
- non-smoker or ex-smoker for at least 1 month
- written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial
Exclusion Criteria:
- existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
- existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient
- existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
- history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
- known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
- subjects with severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
- heart rate < 50 bpm
- laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator
- laboratory values: CRP > 5 mg/L, ASAT > 20 % ULN, ALAT > 10 % ULN, bilirubin > 20 % ULN and creatinine > 0.1 mg/dL
- positive anti-HIV-test (if positive to be verified by western blot), HBs-AG-test (if positive to be verified by test for HBc-IgM) or anti-HCV-test
- history of recurrent episodes of neutropenia or history of agranulocytosis
- acute or chronic diseases which may interfere with the pharmacokinetics of the IMP
- history of or current drug or alcohol dependence
- regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol for male per day
- subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
- regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
- blood donation or other blood loss of more than 400 ml within the last 2 months prior to individual enrolment of the subject
- administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the subject
- regular treatment with any systemically available medication
- treatment with medicinal products which might cause neutropenia or agranulocytosis
- subjects, who report a frequent occurrence of migraine attacks
- subjects suspected or known not to follow instructions
- subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deferiprone 500 Lipomed film-coated tablets
Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
|
|
Active Comparator: Ferriprox® film-coated tablets
Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration versus time curve (AUC0-tlast) for deferiprone
Time Frame: 8 hours interval
|
8 hours interval
|
Peak Plasma Concentration (Cmax) for deferiprone
Time Frame: 8 hours interval
|
8 hours interval
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with treatment-related adverse events
Time Frame: from fist dose until discharge of the subject (approx. 2 weeks)
|
from fist dose until discharge of the subject (approx. 2 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
November 22, 2016
First Submitted That Met QC Criteria
November 29, 2016
First Posted (Estimate)
December 2, 2016
Study Record Updates
Last Update Posted (Estimate)
December 7, 2016
Last Update Submitted That Met QC Criteria
December 6, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1221def09ct
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on Deferiprone 500Mg Tablet
-
ApoPharmaCompleted
-
ApoPharmaAlgorithme Pharma IncCompleted
-
Neuroscience Trials AustraliaThe Florey Institute of Neuroscience and Mental HealthActive, not recruitingMild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's DiseaseAustralia
-
Tanta UniversityCompleted
-
Fortune Pharmacal Co., Ltd.Chinese University of Hong KongCompleted
-
Helwan UniversityCompleted
-
Consorzio per Valutazioni Biologiche e FarmacologicheEuropean CommissionCompletedChronic Iron OverloadItaly, Cyprus, Egypt
-
Chang Gung Memorial HospitalRecruiting
-
British Columbia Cancer AgencyBC Cancer Foundation; Pancreatic Cancer CanadaUnknownResectable Pancreatic Ductal AdenocarcinomaCanada
-
Hugo LovheimCompletedAlzheimer Disease | Herpes Simplex | Mild Cognitive ImpairmentSweden